ATHERSYS, INC / NEW: Nasdaq/NYSE listing notice — Athersys receives Nasdaq delisting notice; BARDA rejects MultiStem for ARDS trial

ATHERSYS, INC / NEW

Nasdaq will suspend trading of common stock at open on Oct 18, 2023 due to failure to meet Market Value of Listed Securities requirement.
Company does not intend to appeal delisting determination; expects stock to trade on OTC market.
BARDA notified Athersys on Oct 13, 2023 that MultiStem was not selected for phase 2 ARDS platform trial.
Company had until Oct 10, 2023 to regain compliance; Panel determined compliance not demonstrated.

item 3.01 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

ATHERSYS, INC / NEW received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

October 16, 2023, the Company received a delisting determination letter from Nasdaq advising the Company that the Panel had determined that the Company was unable to demonstrate compliance with the MVLS Requirement. As a result trading of the Company’s common stock will be suspended at the opening of business on October 18, 2023, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission, removing the Company’s securities from listing and registration on Nasdaq. The Company may, but currently does not intend to, request an appeal of the Panel's determination with Nasdaq.

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001437749-23-028460

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.